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Bloodstream infections (BSIs) are a signiﬁcant cause of morbidity and mortality. Successful patient out-
comes are diminished by a failure to rapidly diagnose these infections and initiate appropriate therapy. A rapid
and reliable diagnostic platform of high sensitivity is needed for the management of patients with BSIs. The
combination of an RNA-dependent nucleic acid sequence-based ampliﬁcation and molecular beacon (NASBA-
MB) detection system in multiplex format was developed to rapidly detect medically important BSI organisms.
Probes and primers representing pan-gram-negative, pan-gram-positive, pan-fungal, pan-Candida, and pan-
Aspergillus organisms were established utilizing 16S and 28S rRNA targets for bacteria and fungi, respectively.
Two multiplex panels were developed to rapidly discriminate bacterial or fungal infections at the subkingdom/
genus level with a sensitivity of 1 to 50 genomes. A clinical study was performed to evaluate the accuracy of this
platform by evaluating 570 clinical samples from a tertiary-care hospital group using blood bottle samples. The
sensitivity, speciﬁcity, and Youden’s index values for pan-gram-positive detection and pan-gram-negative
detection were 99.7%, 100%, 0.997 and 98.6%, 95.9%, 0.945, respectively. The positive predictive values (PPV)
and the negative predictive values (NPV) for these two probes were 100, 90.7, and 99.4, 99.4, respectively.
Pan-fungal and pan-Candida probes showed 100% sensitivity, speciﬁcity, PPV, and NPV, and the pan-Aspergil-
lus probe showed 100% NPV. Robust signals were observed for all probes in the multiplex panels, with signal
detection in <15 min. The multiplex real-time NASBA-MB assay provides a valuable platform for the rapid
and speciﬁc diagnosis of bloodstream pathogens, and reliable pathogen identiﬁcation and characterization can
be obtained in under 3 h.
Bloodstream infections (BSIs) are a signiﬁcant cause of mor-
bidity and mortality in the United States. Approximately
250,000 nosocomial BSIs occur annually, with a crude mortal-
ity rate of 20 to 50% (2, 17, 38). Based on data from death
certiﬁcates, BSIs are the 10th leading cause of death in the
United States (33), and the age-adjusted death rate has risen
by 78% during the past two decades (10). The mortality rates
of BSI patients are increased with measurable delays in the
institution of effective, appropriate antimicrobial therapy (19,
35). Inadequate therapy was an independent determinant of
mortality for individual organisms such as Candida species
(21). Yu et al., in a U.S. multicenter study, found that failure
to start antimicrobial therapy within 24 h of illness onset was
strongly correlated with a higher probability of a 28-day mor-
tality (49). A rapid and reliable diagnosis may be the optimal
method for avoiding such delays in the treatment of BSIs.
A variety of microorganisms can cause BSIs. A nationwide
surveillance study showed that gram-positive bacteria, gram-
negative bacteria, and fungi (including yeasts and molds)
caused 65, 25, and 9.5% of monomicrobial BSIs, respectively.
The most common organisms associated with BSIs are the
coagulase-negative staphylococci (CoNS), Staphylococcus au-
reus, Enterococcus spp., and Candida spp. and the gram-nega-
tive bacilli Escherichia coli and Klebsiella spp.(47). The conven-
tional diagnostic test for BSI is blood culture, which usually is
speciﬁc but can have limited sensitivity and is inherently slow in
providing complete diagnostic information (14, 37). Even after
the detection of growth in cultured blood (usually not before 6
to 12 h of incubation), conventional blood cultures require at
least another 24 to 48 h for the deﬁnitive identiﬁcation of the
pathogen and the assessment of resistance to antibiotics (4,
37). In recent years, real-time PCR assays have been developed
for bacterial and fungal detection from clinical samples (23, 32,
48). The limit of detection was observed as 40, 50, or 2,000
CFU/ml for E. coli, group B Streptococcus spp., and Listeria
monocytogenes, and it was 18 CFU/ml for Candida species. The
nucleic acid extraction and the PCR ampliﬁcation could be
done in about 4 h. Compared to current culture-based and
biochemical methods, nucleic acid sequence-based ampliﬁca-
tion (NASBA) assays may be the most promising diagnostic
approach, because they offer the ultrasensitive detection of
pathogens from blood. Despite this progress, current PCR-
based diagnostics have some inherent limitations. A variety of
pathogen species-speciﬁc PCR-based assays are available;
however, the probes developed are species speciﬁc, which re-
stricts the range of pathogens that can be detected in a single
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 assay. Therefore, the assays are best applied when a speciﬁc
infection is suspected (37), which is rarely the case during the
early stages of BSIs. In addition, a positive signal does not
necessarily reﬂect viable microorganisms (25), as the ampliﬁ-
cation of DNA from dead cells can confuse clinical manage-
ment, especially following therapy. Importantly, some ampli-
ﬁed detection methods generally require a growth enrichment
step, i.e., inoculation and growth in blood culture bottles, to
achieve the sensitivity necessary for pathogen detection and
identiﬁcation.
The universal detection of bacteria or fungi in blood using
broad-range PCR assays has been described (1, 16, 22, 42), but
interpretations can be difﬁcult, as assay contaminants can
cause false-positive results (37). The early detection of BSIs
requires reliable sensitivity, around 10 CFU/ml of blood for
bacteria and fungi, which is below the level of most existing
diagnostic platforms. As an alternative to PCR, NASBA pro-
vides the ultrasensitive detection of nucleic acids. It is an iso-
thermal process that selectively ampliﬁes RNA even in the
presence of genomic DNA (44). The reaction is highly robust,
resulting in 10
12 ampliﬁed copies of template in a 30-min assay
(12), which is comparable to a nested PCR in terms of sensi-
tivity. When used to target rRNA genes, which are present in
multiple copies in the genomes and expressed at a high level
(thousands of copies per cell) in all known human bacterial
and fungal pathogens, a NASBA-based platform is capable of
high-level detection. It detects both live and dead cells. The
ampliﬁed single-stranded RNA can be detected easily in real
time by molecular beacon (MB) probes, which are small, self-
reporting, single-stranded nucleic acid hairpin probes that
brightly ﬂuoresce when bound to their targets (45). MB probes
offer a superior detection modality to perform real-time
NASBA assays, which are rapid, highly speciﬁc, and sensitive.
To address the special considerations of BSIs, we have de-
veloped a real-time NASBA-MB platform that rapidly identi-
ﬁes medically important bacterial and fungal pathogens for
BSI. A cascade pathogen detection and identiﬁcation approach
was developed that recognizes increasing complexity ranging
from kingdom-speciﬁc (e.g., pan-fungal) targets to genus-spe-
ciﬁc (e.g., pan-Candida and pan-Aspergillus) and species-spe-
ciﬁc targets to drug resistance targets. The bacterial primers
and probes target 16S rRNA genes, while the fungal assays
target the 28S rRNA genes. This is the ﬁrst report of a com-
prehensive NASBA-based platform for the rapid detection at
the genus level of the major bacteria and fungi that are re-
sponsible for BSIs. This platform is suitable for use in simplex
or multiplex assays incorporating a range of probes and primer
sets to meet a variety of clinical laboratory detection needs.
This initial proof-of-concept study was designed to assess the
technical feasibility of this method to detect a large variety of
bloodstream pathogens. Although the ﬁnal goal of a rapid
diagnostic is detection from directly drawn blood samples,
these studies are essential to evaluate the potential of the
ampliﬁcation system, primers, and probes. Technical parame-
ters evaluated included assay sensitivity and speciﬁcity. To
evaluate the overall accuracy of this platform, a clinical study
was performed from a tertiary-care hospital group using blood
bottle samples.
MATERIALS AND METHODS
Bacterial and fungal strains. Bacterial strains of Staphylococcus aureus, Staph-
ylococcus epidermidis, Enterococcus faecium, Enterococcus faecalis, Escherichia
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae, and
Acinetobacter spp. and fungal strains of Candida albicans, Candida glabrata,
Candida krusei, Candida tropicalis, Candida parapsilosis, Candida dubliniensis,
Candida guilliermondii, Cryptococcus neoformans, Saccharomyces cerevisiae, As-
pergillus fumigatus, Aspergillus ﬂavus, Aspergillus terreus, and Aspergillus niger were
obtained from the historical stock of the Public Health Research Institute
(PHRI), which is collected from many sites across North America and Europe
(Table 1).
Bacterial and fungal cultures. All reference bacterial strains were cultured on
Luria-Bertani (LB) agar at 37°C, except for S. aureus strains that were grown on
mannitol salt agar (MSA) at 37°C. Candida spp. reference strains were grown
and maintained on yeast extract-peptone-dextrose (YPD) agar at 30°C, and
Aspergillus spp. reference strains were cultured on potato dextrose agar (PDA) at
37°C. Brain heart infusion (BHI) medium, LB broth, or YPD broth was used to
prepare overnight cultures for the nucleic acid extraction from bacteria or Can-
dida reference strains, respectively.
Primers and MB design. 16S and 28S rRNA were chosen to be our detection
targets for bacteria and fungi, respectively. The 16S rRNA gene sequences from
12 bacterial species were obtained from online databases (Table 2). The se-
quences were aligned using the online program ClustalW from the European
Bioinformatics Institute (http://www.ebi.ac.uk/Tools/clustalw/index.html). Simi-
larly, 28S rRNA gene sequences for 15 different fungal species were collected
and aligned (Table 2). For bacteria, one region highly conserved for gram-
positive bacteria but variable for gram-negative bacteria was selected as the
diagnostic target for the pan-gram-positive probe. On the contrary, a region
conserved for all of the gram-negative bacteria but variable for other microbes
was chosen as the diagnostic target for the pan-gram-negative probe. Based on
this principle, pan-fungal, pan-Candida, and pan-Aspergillus targets were selected
accordingly. MB probes were designed by adding two artiﬁcial arm sequences to
TABLE 1. Bacterial and fungal strains used in this study
Species and organism type No. of
strains
Reference
strain Source
Gram-positive bacteria
Staphylococcus aureus 8 MRSA-9897 Clinical strain
Staphylococcus epidermidis 8 10683 Clinical strain
Enterococcus faecium 8 11936 Clinical strain
Enterococcus faecalis 8 9199 Clinical strain
Gram-negative bacteria
Escherichia coli 8 8781 Clinical strain
Enterobacter cloacae 8 10623 Clinical strain
Pseudomonas aeruginosa 8 10470 Clinical strain
Acinetobacter baumannii 8 10437 Clinical strain
Klebsiella pneumoniae 8 20856 Clinical strain
Candida spp.
Candida albicans 8 90028 ATCC strain
Candida glabrata 8 90030 ATCC strain
Candida krusei 8 6258 ATCC strain
Candida tropicalis 8 750 ATCC strain
Candida parapsilosis 8 22019 ATCC strain
Candida guilliermondii 8 6260 ATCC strain
Candida lusitaniae 4 200950 ATCC strain
Candida dubliniensis 8 3949 NCPF strain
Aspergillus spp.
Aspergillus fumigatus 8 293 ATCC strain
Aspergillus ﬂavus 8 204304 ATCC strain
Aspergillus terreus 8 9151 Merck strain
Aspergillus niger 8 9508 ATCC strain
Other fungi
Cryptococcus neoformans 1 208821 ATCC strain
Saccharomyces cerevisiae 1 Y55 Laboratory strain
2068 ZHAO ET AL. J. CLIN.M ICROBIOL.
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 both ends of the target sequence. The secondary structure of the MB was
evaluated by the software OligoAnalyzer 3.0 (http://www.idtdna.com/analyzer
/Applications/OligoAnalyzer/). The MBs were labeled with the ﬂuorophores
5-carboxyﬂuorescein (FAM), 6-carboxy-2,4,4,5,7,7-hexachloroﬂuorescein (HEX),
CAL ﬂuor red (CR610), and Quasar 670 (Q670) at the 5 end and with benzoic
acid succinimidyl ester (dabcyl) or black hole quencher at the 3 end. The MBs
were purchased from Biosearch Technologies, Inc., Novato, CA. The pan-gram-
negative MB has a perfect target sequence for most bacterial species tested in
this study, except for Acinetobacter spp. and Pseudomonas spp., which both have
two mismatches with the pan-gram-negative beacon. Therefore, two individual
beacons targeting Acinetobacter spp. and Pseudomonas spp. were designed in the
same region covered by the pan-gram-negative primers, and they were mixed
with the pan-gram-negative MB for the following experiments. Similarly, three
patch probes for pan-gram-positive MB (16S GP v1.21 to 16S GP v1.23) (Table
3) were designed, because three gram-positive species (Corynebacterium sp.,
Propionibacterium sp., and Micrococcus sp.) from the clinical samples were
missed by the pan-gram-positive probe. NASBA primers also were designed
based on the sequence alignments. A T7 promoter sequence was added at the 5
end of each P1 primer. All MBs and NASBA primers used in this study are listed
in Table 3.
Extraction of TNA and RNA. A 200-l aliquot of test culture was mixed with
800 l NucliSENS lysis buffer (bioMe ´rieux, Durham, NC) in lysing matrix tubes
(MP, Biomedicals, Inc., Solon, OH) and vigorously vortexed on a FastPrep
instrument (MP, Biomedicals, Inc., Solon, OH) for 45 s, followed by a 30-min
incubation at 37°C. Cell lysates were centrifuged at 16,000  g for 10 min, and
then 800 l of supernatant was transferred and mixed with 2 ml NucliSENS lysis
buffer in the NucliSENS easyMAG (bioMe ´rieux) sample cartridge for the total
nucleic acid (TNA) extraction. Magnetic silica solution was added, and the TNA
extraction was performed according to the easyMAG user manual. The ﬁnal
elution volume of the TNA for each dilution was 110 l. For Aspergillus spp.,
conidia were collected from an Aspergillus fumigatus culture grown on a PDA
plate at 37°C for 3 days, using sterile saline with 0.01% Tween 20. The conidial
suspension was counted under a microscope using a disposable cell counting
chamber, and 200 lo f1 0
7 CFU/ml conidial suspension was extracted for total
nucleic acids. Tenfold serial dilutions were made from the extracts. In some
experiments, pure RNA was isolated using the RNeasy kit according to the
procedure of the manufacturer (Qiagen, Valencia, CA). The RNA concentration
was determined by spectrophotometry using a Nanodrop DN1000 device (Nano-
drop Techonologies, DE), and the 260-nm wavelength/280-nm wavelength and
260-nm wavelength/230-nm wavelength ratios were calculated.
Real-time NASBA. The NASBA reactions were performed with the
NucliSENS basic kit version 2 (bioMe ´rieux). Reactions were carried out in a total
volume of 20 l containing reagent mix, 0.2 M each primer, 0.1 M MB, 5 l
of RNA or TNA template, and 5 l of NASBA enzyme mix (nucleic acid-free
enzyme; provided by bioMe ´rieux, France). The enzyme mixture contained T7
RNA polymerase, avian myeloblastosis virus reverse transcriptase, RNase H, and
bovine serum albumin, and the mixture was added to the reaction mixture after
a two-step incubation of 2 min at 65°C and 2 min at 41°C. For simplex NASBA
assays, ampliﬁcation and real-time detection were performed on the NucliSENS
EasyQ analyzer (bioMe ´rieux) at 41°C for 90 min. The ﬂuorescence signal was
measured with an interval time of 30 s for each independent reaction at two
wavelengths using the accompanying NucliSENS EasyQ Director software (ver-
TABLE 2. Strains and sequences used for primer and MB design
Species and organism type Strain Accession no. Region
Gram-positive bacteria
Staphylococcus aureus MRSA252 NC_002952 16S rRNA
Staphylococcus epidermidis RP62A NC_002976 16S rRNA
Streptococcus pneumoniae TIGR4 AAGY02000123 16S rRNA
Enterococcus faecium DO ctg565 AAAK03000115 16S rRNA
Enterococcus faecalis V583 NC_004668 16S rRNA
Gram-negative bacteria
Escherichia coli O157:H7 EDL933 NC_002655 16S rRNA
Enterobacter cloacae CP1 DQ089673 16S rRNA
Klebsiella pneumoniae MGH 78578 NC_009648 16S rRNA
Pseudomonas aeruginosa PAO1 NC_002516 16S rRNA
Acinetobacter baumannii ADP1 NC_005966 16S rRNA
Proteus mirabilis HI4320 AM942759 16S rRNA
Haemophilus inﬂuenzae 86–028NP NC_007146 16S rRNA
Candida spp.
Candida albicans SC5314 AACQ01000295 28S rRNA
Candida glabrata CBS138 AY198398 28S rRNA
Candida krusei NRRL Y-5396 EF550222 28S rRNA
Candida tropicalis MYA-3404 AAFN01000124 28S rRNA
Candida parapsilosis 317 Sanger Institute
a 28S rRNA
Candida guilliermondii ATCC 6260 AAFM01000051 28S rRNA
Candida lusitaniae ATCC 42720 AAFT01000066 28S rRNA
Candida dubliniensis CD36 Sanger Institute
b 28S rRNA
Aspergillus spp.
Aspergillus fumigatus Af293 AAHF01000017 28S rRNA
Aspergillus ﬂavus NRRL3357 AAIH01002203 28S rRNA
Aspergillus terreus NIH 2624 Broad Institute
c 28S rRNA
Aspergillus niger CBS 513.88 NT_166520 28S rRNA
Other fungal species
Cryptococcus neoformans B-3501A AAEY01000011 28S rRNA
Saccharomyces cerevisiae RM11-1a AAEG01000105 28S rRNA
Neosartorya ﬁscheri NRRL 181 AAKE03000097 28S rRNA
a Genome sequence data used in this study were produced by the Pathogen Genomics group at the Wellcome Trust Sanger Institute and are available from
http://www.sanger.ac.uk/sequencing/Candida/parapsilosis/.
b Genome sequence data used in this study were produced by the Pathogen Genomics group at the Wellcome Trust Sanger Institute and are available from
http://www.sanger.ac.uk/sequencing/Candida/dubliniensis/.
c Sequence data were produced by the Aspergillus terreus sequencing project at the Broad Institute of Harvard and MIT (http://www.broad.mit.edu).
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 sion 2). For multiplex NASBA assays, reactions were carried out on a Stratagene
Mx3005P real-time PCR system (Stratagene, La Jolla, CA) with the setting of
180 cycles at 41°C with 30 s for each cycle. The ﬂuorescence signal was measured
once for each cycle. The cutoff threshold for the positive signal was set as 10%
higher than the end point signal from the no-template control, which used 5 l
of nuclease-free water instead of nucleic acids in the reaction mixture. The time
to positive was deﬁned as the time point when the positive signal crossed the
threshold. Two multiplex real-time NASBA assays (pan-gram positive/pan-gram
negative and pan-fungal/pan-Candida/pan-Aspergillus) were developed for bac-
terial and fungal detection, respectively.
Preliminary in vitro speciﬁcity and sensitivity. (i) Quantifying target tem-
plate. An artiﬁcial rRNA fragment for each pathogen was synthesized by in vitro
transcription from a PCR product containing the corresponding genomic DNA
using a speciﬁc primer set (Table 4), of which the forward primer was linked with
a T7 promoter sequence. The speciﬁc PCR products either were puriﬁed by
paramagnetic beads (Agencourt AMPure, Beverly, MA) or extracted from aga-
rose gels (Monta ´ge; Millipore, Billerica, MA). After puriﬁcation, the PCR prod-
uct was transcribed in vitro for1ha t37°C using an RNAMaxx High Yield
Transcription kit (Stratagene) and then treated by RNase-free DNase I (Am-
bion, Austin, TX) for 30 min at 37°C. RNA products were puriﬁed using the
RNeasy kit according to the RNA cleanup protocol (Qiagen). Puriﬁed RNA
targets were quantiﬁed by a Quant-iT RiboGreen RNA quantiﬁcation kit (Mo-
lecular Probes, Invitrogen, Carlsbad, CA). For TNA quantiﬁcation, overnight
cultures were subcultured in the same broth and grown for 3 to 4 h until log
phase and then were harvested by centrifugation at 4,000 rpm for 5 min at 4°C.
The cells were washed twice with sterile phosphate-buffered saline (PBS). The
numbers of structurally intact cells were determined microscopically using a
disposable cell counting chamber. Cultures were serially diluted from 10
7 to 10
0
CFU/ml accordingly. TNA was extracted from each dilution as described above.
The accurate CFU was enumerated by plating 100 l of each dilution onto LB
agar for bacteria (MSA for S. aureus) or YPD agar for Candida and incubating
it at 37°C for 24 h.
(ii) Sensitivity and speciﬁcity testing. The sensitivities of the real-time
NASBA assays were assessed by amplifying both in vitro RNA transcripts and
TNAs isolated from serial dilutions of the target organism cultures. As described
above, the in vitro RNA transcripts were synthesized, puriﬁed, and quantiﬁed,
and the number of RNA copies was calculated according to the concentration
and the size of the RNA transcript. Tenfold serial dilutions were prepared
covering a range of 8-log (10
7 to 10
0) copies of RNA molecules per NASBA
reaction. These dilutions of RNA were added directly into the NASBA mix. For
TABLE 3. Primers and MBs for each assay
Oligonucleotide or primer
and organism type Type Sequence (5–3)
h Position
Gram-positive bacteria
PLK1 Forward primer TACGGGAGGCAGCAGT 351–366
a
PLK2N v1.4 Reverse primer AATTCTAATACGACTCACTATAGGGGCTGCTGGCACGTA
GTTAGCCGTGGCTTTC
533–504
a
16S GrP MB MB CGAGCTAGCAACGCCGCGTGAGTGAAGCTCG 401–419
a
16S GP v1.21 MB CGAGCTAGCAACGCCGCGTGGGTGAAGCTCG 401–419
a
16S GP v1.22 MB CGAGCTAGCAACGCCGCGTGAGGGAAGCTCG 401–419
a
16S GP v1.23 MB CGAGCTAGCGACGCCGCGTGGGGGAAGCTCG 401–419
a
Gram-negative bacteria
Grm neg 16S P2 Forward primer CCTGATGCAGCCATGCCGCGTG 385–406
b
Grm neg 16S P1 Reverse primer AATTCTAATACGACTCACTATAGGGCACGGAGTTAGCC
GGTGCTT
517–498
b
Grm neg 16S MB MB CGAGCTTGAAGAAGGCCTTCGGGTTGTAAAGAGCTCG 409–433
b
Grm neg16S-Acin MB CGAGCTTGAAGAAGGCCTTATGGTTGTAAAGAGCTCG 397–421
c
Grm neg16S-Pseu MB CGAGCTAGCACTTTAAGTTGGGAGGAAGCTCG 427–446
d
Bacteria
GP/GN P1
g Reverse primer AATTCTAATACGACTCACTATAGGGGTATTACCGCGGCT
GCTGGCAC
544–523
a
Fungi
28SPF P2 Forward primer CGGCTCTTCCTATCATACCG 2850–2869
e
28SPF P1 Reverse primer AATTCTAATACGACTCACTATAGGGCTAAACCCAGCTCA
CGTTCC
2931–2912
e
28SPF MB MB CGCGATATTCGGTAAGCGTTGGATTGATCGCG 2877–2896
e
Candida species
28SPC P2 Forward primer GGAATCCGCTAAGGAGTGTG 1246–1265
e
28SPC P1 Reverse primer AATTCTAATACGACTCACTATAGGGCCATCCATTTTCAG
GGCTAGT
1309–1289
e
28SPC MB MB CGCGATTAACAACTCACCGGCCGAATATCGCG 1266–1285
e
Aspergillus species
28SPAS Forward primer CAGCAGTTGGACATGGGTTA 1503–1522
f
28SPAASN Reverse primer AATTCTAATACGACTCACTATAGGGGAGAATCCACATCC
AGGTGC
1625–1606
f
28SPAMB MB CGACCGGCATAGGGAAGTTCCGTTTGGTCG 1534–1553
f
a The position is based on S. aureus MRSA252 NC_002952.
b The position is based on E. coli O157:H7 EDL933 NC_002655.
c The position is based on A. baumannii ADP1 NC_005966.
d The position is based on P. aeruginosa PAO1 NC_002516.
e The position is based on C. albicans SC5314 AACQ01000295.
f The position is based on A. fumigatus Af293 AAHF01000017.
g The primer was used for bacterial multiplex detection.
h T7 promoter sequences are labeled in italics, and beacon arm sequences are underlined.
2070 ZHAO ET AL. J. CLIN.M ICROBIOL.
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 the TNA isolated from the bacterial or fungal culture serial dilutions, the
NASBA assay was performed on each of these extracts. To mimic the clinical
environment, blood culture bottles containing 8 ml of whole blood were spiked
with 10-fold serially diluted bacterial cultures of Enterobacter cloacae and yeast
cultures of Candida glabrata and were subjected to TNA extraction. A 200-l
aliquot of the spiked blood bottle culture was used for TNA extraction at a
concentration ranging from 4  10
6 to 4  10
0 CFU/ml. Blood culture bottles
lacking the spiking pathogen were subjected to extraction in parallel as the
negative control. All of the real-time NASBA assays described above were
repeated at least three times. Preliminary probe speciﬁcity was evaluated by
testing the nucleic acids from the target organisms, as well as the nucleic acids
from other related microbes. For instance, the pan-gram-positive probe was
tested against nucleic acids from four gram-positive bacterial species as well as a
panel of ﬁve gram-negative species, eight Candida spp., C. neoformans, S. cer-
evisiae, and four Aspergillus spp., as listed in Table 1. The no-template control
also was tested in parallel, and at least eight TNA samples from different clinical
isolates of the same species were tested for each probe.
Clinical evaluation: sample collection, preparation, and NASBA detection. To
assess the clinical performance of the NASBA assays, aerobic and anaerobic
blood culture bottles submitted for routine clinical testing were processed ac-
cording to the manufacturer’s instructions in either the BacT/Alert 3D (bio-
Me ´rieux) or the BacTec 9240 (Becton Dickinson, Sparks, MD) automated blood
culture system. Five-milliliter aliquots from 520 randomly selected positive blood
culture bottles (BacTec Aerobic Plus, n  250; BacTec Anaerobic Plus, n  232;
BacTec Anaerobic Lytic, n  6; BacTec Peds Plus, n  12; and BacT/Alert
Aerobic, n  20) were collected at the time blood bottles were ﬂagged as positive
by the automated blood culture systems and processed for routine microbiologic
testing. The identiﬁcation of the organism(s) present in the positive blood culture
bottles was not known at the time of selection. They were selected in this manner
so as not to bias results and to mimic the pattern of clinical isolates routinely
encountered in our laboratory. The blood culture aliquots were deidentiﬁed by
the North Shore-Long Island Jewish Health System Laboratories and stored at
4°C until shipment to PHRI on a weekly basis. Gram stain and culture on solid
media were performed according to standard laboratory procedures for microbe
identiﬁcation and the determination of sensitivity to antibiotics. Microbe iden-
tiﬁcation and the methicillin susceptibility proﬁles for S. aureus isolates were not
provided to PHRI until the completion of the study. In addition, 5-ml aliquots
from 50 negative blood culture bottles, collected on day 5 at the completion of
routine culture, also were deidentiﬁed. The blood aliquots were stored at 4°C and
transported within 7 days to PHRI for real-time NASBA identiﬁcation. Brieﬂy,
200 l of the blood culture was mixed with 800 l of a mixture of lysis buffer and
proteinase K (25 g/ml). FastPrep for 45 s, as described above, was followed by
a 1-h incubation at 55°C and then a hard spin of the lysates at 16,000  g. The
supernatants were processed as described for TNA extraction from laboratory
cultures. The ﬁnal volume of each TNA sample eluate was 110 l, 5 l of which
was used for each real-time NASBA assay. Blood bottle samples were tested by
multiplex real-time NASBA assays. Studies were performed under an Institu-
tional Review Board-approved protocol.
Statistical evaluation. After breaking the code of the blinded blood bottle
samples, the accuracy of the real-time multiplex NASBA assay was assessed by
calculating the sensitivity, speciﬁcity, Youden’s index (6), and predictive values
for each probe.
RESULTS
Speciﬁcity of the broad-range real-time NASBA platform.
The speciﬁcity of the assay was deﬁned as the ability to exclu-
sively detect the target of interest. Like PCR-based methods,
broad-range NASBA assays also are more vulnerable to trace
amounts of nucleic acid contamination than the species-spe-
ciﬁc assays, which can lead to false-positive results. To over-
come this potential problem, a nucleic acid-free enzyme mix
(R&D Group, bioMe ´rieux, France) was used for ampliﬁcation
in the broad-range bacterial and fungal pathogen detection
system. All probes showed 100% speciﬁcity in initial tests using
reference strains. Speciﬁc signal was observed for all target
species but not for any other nontarget organism. Pan-gram-
positive and pan-gram-negative probes were able to detect four
(S. aureus, S. epidermidis, E. faecium, and E. faecalis) and ﬁve
(E. coli, P. aeruginosa, A. baumannii, E. cloacae, and K. pneu-
moniae) medically important species, respectively, and no
cross-reactivity was observed between each group or with
fungi. Pan-fungal, pan-Candida, and pan-Aspergillus probes
also demonstrated 100% speciﬁcity. Eight Candida species (C.
albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, C.
guilliermondii, C. lusitaniae, and C. dubliniensis), four Aspergil-
lus species (A. fumigatus, A. ﬂavus, A. niger, and A. terreus),
Cryptococcus neoformans, and Saccharomyces cerevisiae (Table
1) were detected easily by the pan-fungal probe without any
cross-reactivity with the bacterial probes. Pan-Candida and
pan-Aspergillus probes selectively recognized all of the Candida
or Aspergillus species among all of the fungal species listed in
Table 1. All probes were validated with at least eight clinical
isolates.
Sensitivity of real-time NASBA assays: simplex assays. C.
albicans and A. fumigatus were selected as representative spe-
cies for the pan-fungal, pan-Candida, and pan-Aspergillus sen-
sitivity evaluations. As shown in Table 5, the analytical sensi-
tivity of the assay was 10
4 copies of target RNA transcripts for
pan-fungal and pan-Candida assay and 10
3 copies of target
RNA for pan-Aspergillus detection. To assess the effect and the
TABLE 4. Primers used for in vitro transcription
Primer Sequence (5–3) Position
SA16S F AATTCTAATACGACTCACTATAGGGTAACGGCTTACCAAGGCAAC 269–288
SA/Enterc16S R ACCTTCCGATACGGCTACCT 1533–1514
a
Enterc16S F AATTCTAATACGACTCACTATAGGGCACATTGGGACTGAGACACG 303–322
SE16S F AATTCTAATACGACTCACTATAGGGCAAGTCGAGCGAACAGACGA 59–78
SE16S R TGTCACCGGCAGTCAACTTA 1181–1162
Ecoli/Kleb16S F AATTCTAATACGACTCACTATAGGGGATCATGGCTCAGATTGAACG 15–35
b
Ecoli/Kleb16S R GCTGGCAACAAAGGATAAGG 1132–1113
b
28SPF F AATTCTAATACGACTCACTATAGGGGAGGCTAGAGGTGCCAGAAA 2756–2775
c
28SPF R TCTGACTTAGAGGCGTTCAGC 3101–3081
c
Calb28S F AATTCTAATACGACTCACTATAGGGCGATACTGCCAGCCTAGACC 566–585
Calb28S R CGCTCTTCCAGCCATAAGAC 1751–1732
Afum28S-F AATTCTAATACGACTCACTATAGGGGTGAAGCTCCTTCGACGAGT 250–269
Afum28S-R TCTCCGCGTTCAGTTACGTT 1651–1632
a The position is based on the S. aureus 16S sequence from NC_002952.
b The position is based on the E. coli 16S sequence from NC_002655.
c The position is based on the C. albicans 28S sequence from AACQ01000295.
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 efﬁciency of the extraction process, the TNAs isolated from
serially diluted fungal cultures were used to evaluate the limit
of detection of the assay. All fungal probes were able to detect
fewer than 2 CFU of target organisms. Similar sensitivities
were observed for both pan-gram-positive and pan-gram-neg-
ative probes, with a detection limit ranging from 10
3 to 10
4
RNA copies and around 1 to 5 CFU of target organisms (Table
5). To investigate the applicability of our pan-NASBA assay,
speciﬁcity and sensitivity tests were performed using TNAs
extracted from blood culture bottles containing whole blood
that had been spiked with serially diluted C. glabrata or E.
cloacae cultures. Robust signals were detected at as low as 0.28
CFU of C. glabrata by the pan-fungal and the pan-Candida
probes, and the pan-gram-negative probe could detect 3.1
CFU of E. cloacae in a single NASBA reaction.
Multiplex assays. Compared to the ultrasensitive simplex
NASBA reactions, multiplex NASBA assays were less sensitive
(10- to 100-fold) for most of the probes. Interactions among
different MBs and primer sets were expected to occur in these
multiplex detections, which accounts for the diminished sensi-
tivity. To improve the sensitivity, one common P1 (GP/GN P1)
was designed and used for the bacterial panel. The common P1
demonstrated that approximately 10
5 to 10
6 copies of target
RNA molecules or 5 to 50 CFU of organisms (Table 5, Fig. 1)
could be detected by the pan-gram-positive/pan-gram-negative
assays. Additional patch probes for gram-positive bacteria did
not change the sensitivity of the multiplex assay. In contrast,
less competition was seen in the fungal panel, of which the
detection limit ranged from 10
4 to 10
5 copies of C. albicans or
A. fumigatus RNA or around 1 CFU of target organism (Table
5, Fig. 2).
Clinical evaluation. A total of 520 randomly selected sam-
ples from positive blood bottles were identiﬁed to the subk-
ingdom or genus level by multiplex NASBA, and the results
were compared to those obtained by conventional culture sys-
tems. Based on the culture identiﬁcation, 362 samples con-
tained gram-positive bacteria, 149 samples contained gram-
negative bacteria, and 10 samples contained Candida spp. A
wide BSI pathogen spectrum was seen in these samples, con-
sisting of eight gram-positive bacterial genera and 21 species
(Corynebacterium spp. [including C. jeikeium], Enterococcus
spp. [E. casseliﬂavus, E. faecalis, E. faecium, and E. gallinarum],
Lactobacillus casei, Micrococcus sp., Propionibacterium acnes,
Staphylococcus aureus [methicillin sensitive and resistant],
CoNS [including S. lugdunensis], and Streptococcus spp. [S.
agalactiae, S. bovis, S. milleri group, S. mitis group, S. pneu-
moniae, S. pyogenes, S. sanguis, and S. salivarius]), 17 gram-
negative bacterial genera and 20 species (Acinetobacter bau-
mannii, Alcaligenes sp., Bacteroides sp., Burkholderia cepacia,
Citrobacter spp. [C. freundii and C. koseri], Enterobacter spp. [E.
aerogenes and E. cloacae], Escherichia coli, Fusobacterium nu-
cleatum, Haemophilus inﬂuenzae, Klebsiella spp. [K. oxytoca and
K. pneumoniae], Morganella morganii, Prevotella loescheii, Pro-
teus mirablis, Providencia stuartii, Pseudomonas aeruginosa, Sal-
monella sp. group B, and Serratia marcescens), and 3 Candida
species (C. albicans, C. parapsilosis, and C. tropicalis). High-
level speciﬁcity was observed for all probes in the multiplex
NASBA detections (Table 6). In a set of controlled experi-
ments, 50 culture-negative blood bottle samples were evalu-
ated and failed to elicit any detectable ﬂuorescent signals. In
addition, full sensitivity as described above was unaltered with
blood bottle media used as the background matrix.
One blood culture, ﬂagged as positive by the automated
blood culture instrument, was culture negative, and the
NASBA assays identiﬁed a gram-negative organism. A second
blood culture collected from the same patient several hours
later grew Pseudomonas aeruginosa. A blood culture from an-
other patient had very poor growth that did not initially allow
for the identiﬁcation of the two pathogens present in the sam-
ple. The NASBA assays were positive for both a gram-positive
and a gram-negative organism. Conventional culture took more
than 1 week to ﬁnally conﬁrm the presence of a gram-positive
rod in the same bottle. A gram-negative rod was not recovered
from this bottle, but another blood culture drawn on the same
day contained E. coli.
It was observed that the uncommon organisms Corynebac-
terium spp., Propionibacterium sp., and Micrococcus sp. were
falsely identiﬁed as gram-negative bacteria. To address this
issue, three patch probes were designed for pan-gram-positive
detection (Table 3). The use of a mixture of four pan-gram-
positive MBs increased the speciﬁcity of pan-gram-positive
detection to 99%. A total of 13 out of 14 missed gram-
positive samples subsequently were picked up by the new pan-
gram-positive detection, and no cross-reaction was seen from
gram-negative bacteria and fungi. In addition, the pan-gram-
negative probe failed to recognize the anaerobe Prevotella loe-
scheii in the clinical blood culture, and no detectable signal was
seen from other probes as well. In control experiments, no
organisms were detected in the 50 negative blood cultures
submitted for testing.
The overall performance of multiplex NASBA assays was
measured by sensitivity, speciﬁcity, Youden’s index, and pre-
dictive values for each primer/probe set (Table 6). High sen-
sitivity (96.1 and 98.6%), speciﬁcity (100 and 95.9%), and
TABLE 5. Sensitivity of real-time NASBA
Probe and species
Sensitivity in simplex
assay
Sensitivity in multiplex
assay
Copy no. CFU/reaction Copy no. CFU/reaction
GrP16S
E. faecium 10
310
4 0.2 10
510
6 2
E. faecalis 10
310
4 0.56 10
5 5.6
S. epidermidis 10
4 4.5 10
6 45
S. aureus 10
4 1.3 10
510
6 13
GrN16S
E. coli 10
4 5.5 10
6 55
A. baumannii 10
4 1.1 10
510
6 11
K. pneumoniae 10
4 1.1 10
510
6 11
E. cloacae 10
4 1.7 10
6 17170
P. aeruginosa 10
4 1.1 10
510
6 11
28SPF
C. albicans 10
310
4 1.8 10
4 1.8
A. fumigatus 10
310
4 0.14 10
4 1.4
28SPC
C. albicans 10
4 1.8 10
5 1.8
28SPA
A. fumigatus 10
3 0.14 10
4 1.4
2072 ZHAO ET AL. J. CLIN.M ICROBIOL.
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 Youden’s indices for pan-gram-positive and pan-gram-nega-
tive detection demonstrate the great accuracy of this multiplex
assay. The positive predictive values (PPV) for pan-gram-pos-
itive and pan-gram-negative probes were 100 and 90.7%, re-
spectively, and the corresponding negative predictive values
(NPV) for these two probes were 91.8 and 99.4% (Table 6).
The relatively low NPV for pan-gram-positive probe and low
PPV for pan-gram-negative probe were due largely to the false
identiﬁcations for three gram-positive organisms, Corynebacte-
rium spp., Propionibacterium acnes, and Micrococcus sp., which
counted for 13/14 samples falsely identiﬁed as gram-negative
pathogens. However, with the addition of the patch probes, the
NPV for the pan-gram positive assay was increased to 99.4%.
Meanwhile, the fungal panel was observed to be highly reli-
able. Both pan-fungal and pan-Candida probes demonstrated
100% sensitivity, speciﬁcity, Youden’s index, PPV, and NPV,
and the pan-Aspergillus probe also showed a 100% negative
predictability (Table 6). It should be noted that the high PPV
needs to be viewed in context with the limited number of
positive fungal cultures obtained in this study. Robust signals
were observed for all probes in the multiplex panels, with
signal detection in less than 15 min.
DISCUSSION
Conventional diagnostic methods for BSIs require several
days to complete, and both false-positive (15, 26, 34) and
false-negative results (24, 40, 41) have been reported. Delayed
FIG. 1. Sensitivity of the multiplex real-time NASBA assay for bacteria. Sensitivity of pan-gram negative (FAM) (A) and pan-gram positive
(HEX) (B) probes in multiplex format using a 10-fold dilution series of TNA isolated from cells of A. baumannii and P. aeruginosa (A) and S. aureus
and E. faecalis (B). Oligonucleotides 16S GrP MB and Grm neg 16S MB and the primer set of PLK1, primer Grm neg 16S P2, and primer GP/GN
P1 were used in this multiplex assay.
VOL. 47, 2009 MOLECULAR BEACON DETECTION OF BLOODSTREAM INFECTIONS 2073
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 diagnosis correlates strongly with the high mortality of BSIs
(19, 35, 49). Thus, there is an urgent need for a rapid and
reliable diagnostic method that will allow clinicians to make
faster and better-informed treatment choices for BSI patients.
In this study, we describe a rapid, highly speciﬁc, and sensitive
diagnostic platform for BSI, using NASBA and MB technology
to perform real-time assays. Five broad-range MBs and the
corresponding primer sets were developed and evaluated in
this study. The primer/probe sets were able to rapidly and
accurately identify most medically important BSI pathogens to
the genus level. Furthermore, the simultaneous detection and
characterization of the BSI pathogen at the subkingdom or
genus level could be done by the two multiplex real-time
NASBA detection panels presented in this study. Reliable
pathogen identiﬁcation and characterization can be obtained
in under 3 h. This approach holds promise for the rapid diag-
nosis of BSIs.
As a powerful diagnostic tool, real-time NASBA has been
used widely for detecting RNA viruses such as enterovirus and
human immunodeﬁciency virus (27, 31, 39), certain microbial
pathogens including Legionella species, Vibrio cholerae, etc.
(18, 30), and pathogens from food and environmental samples
(11, 36). However, only a few studies have reported using
conventional NASBA to detect Candida spp. and Aspergillus
spp. (7, 29, 46), and no real-time NASBA methods had been
reported for BSIs. Conversely, during the past decade, many
PCR-based assays were developed and dominated the methods
used for the identiﬁcation of microorganisms and the diagnosis
of infections. Compared to PCR, a major advantage of
NASBA is the fast ampliﬁcation kinetics. It is an isothermal
process, and the single-stranded RNA amplicons produced can
be used directly for the subsequent rounds of ampliﬁcation or
probe detection without the need for denaturation or strand
separation. When using the multicopy rRNA as the target,
NASBA results in high sensitivity and allows for a faster iden-
tiﬁcation of the pathogens.
The universal PCR-based detection of bacteria or fungi has
been attempted because of its powerful potential to rapidly
detect and identify a broad range of pathogens, but the clinical
value of this testing still is debatable (8). The most signiﬁcant
limitation to date is the potential for DNA or RNA contami-
nation from a variety of uncertain sources, including enzymes,
reagents, nucleic acid extraction kits, columns, water, the en-
vironment, and so on. Attempts to decontaminate PCR mate-
rials (9, 13) are not entirely effective or reproducible. Some
real-time PCR assays were not able to detect pathogens pre-
senting at low levels without reporting false positives caused by
low-level endogenous contamination. In our preliminary ex-
periments, the availability of nucleic acid-free enzyme prepa-
rations and high-quality nucleic acid-free reagents has helped
to eliminate the contamination problem. In this context, ﬁve
broad-range real-time NASBA assays were developed to de-
tect a wide variety of BSI pathogens. Several medically impor-
tant pathogens, including 9 bacterial species and 12 fungal
species, were used to evaluate these real-time NASBA detec-
tions. All of these assays have great selectivity for their target
organisms, and no cross-reaction was observed in tested spe-
cies. The great diversity of bacterial species represented in the
clinical study was extremely helpful in highlighting false-
negative results for three gram-positive bacterial organisms,
Corynebacterium sp., Propionibacterium sp., and Micrococcus
sp., when tested using the original pan-gram-positive probe.
With the exception of immune-compromised persons or per-
sons with indwelling devices, these bacterial species generally
do not cause invasive disease, can be found on human skin, and
usually are present in blood cultures as a result of contamina-
tion during sample collection. However, since there are cir-
cumstances in which these organisms are clinically relevant,
several new pan-gram-positive probes were designed and
tested. The mixture of these new probes and the old pan-gram-
positive probe then could easily detect all species. Similarly,
the pan-gram-negative probe failed to identify Prevotella spp.
from the blood cultures, although a patch probe was not de-
signed against this genus.
The analytical sensitivity tests of the real-time NASBA as-
says were performed. All ﬁve probes were able to detect ap-
proximately 10
3 to 10
4 copies of artiﬁcial RNA targets in one
NASBA reaction, as well as genomic RNA extracted from
around 1 to 5 CFU of bacterial or fungal cultures, assuming
100% efﬁciency of the extraction. In comparison, the limit of
broad-range bacterial detection was 10 to 100 CFU per reac-
tion for E. coli and 100 to 1,000 CFU per reaction for S. aureus
(20, 50) in regular PCR, and 1 to 10 CFU per reaction was
observed in real-time PCR (20, 50). NASBA fungal assays
showed limits of detection comparable to those of pan-fungal
PCR assays (3, 43). The detection limits of pan-Candida and
pan-Aspergillus assays are in agreement with the results re-
ported by other studies that used traditional NASBA detection
(electrochemiluminescence) for Candida spp. (28, 46) or As-
pergillus spp. (29).
The clinical applicability of our real-time multiplex NASBA
assays was evaluated by testing blinded blood cultures. To our
knowledge, this is the ﬁrst study to compare real-time NASBA
assays with the capability to detect a wide range of potential
pathogens to the classical cultural approach for the diagnosis
of BSIs. Since this pilot study was conducted using samples
derived from positive blood culture bottles, one might argue
that there is little beneﬁt to be obtained by using multiple
molecular tests instead of a simple and inexpensive gram stain
as the ﬁrst diagnostic step. This is true for the majority of the
samples tested in this pilot study. However, an example of a
notable exception with a clear diagnostic beneﬁt would be the
identiﬁcation of Candida krusei, since this yeast is intrinsically
resistant to a ﬁrst-line treatment drug, ﬂuconazole. The ulti-
mate goal in the development of such assays is to signiﬁcantly
reduce the time to initial pathogen detection, not to completely
FIG. 2. Sensitivity of the multiplex real-time NASBA assay for fungi. A 10-fold dilution series of in vitro 28S rRNA transcripts for C. albicans
and A. fumigatus were used for the evaluation. Shown is the sensitivity, in multiplex format, of pan-fungal probe (CR610) (A), pan-Candida probe
(FAM) (B), and pan-Aspergillus probe (Q670) (C). The same primer-MB sets for pan-fungal, pan-Candida, and pan-Aspergillus simplex detection
(Table 3) were used in combination for this multiplex assay.
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 replace blood cultures. In the majority of cases, susceptibility
studies still must be performed, and the detection of all patho-
gens must be guaranteed. With improved nucleic acid isolation
and concentration methods, detection from directly drawn
specimens may be possible. However, if this is shown not to be
sufﬁciently sensitive, reducing the time to blood culture testing,
i.e., sampling the bottle before it is ﬂagged as positive, may be
a viable alternative approach.
Although our testing was performed on positive blood cul-
tures, in fact, our real-time NASBA assays demonstrated sev-
eral advantages that could make it a valuable complement to
traditional blood culture for the diagnosis of BSIs. First, the
NASBA assays demonstrated a high predictability to rule out a
BSI. The data also suggest that it can be used for accurate
diagnosis when a pathogen is present. For example, one blood
culture, reported as positive but from which no organism was
grown, was positive by NASBA for a gram-negative organism
and was conﬁrmed by the isolation of P. aeruginosa from an-
other blood culture bottle that became positive hours after the
ﬁrst blood bottle. The earlier detection of the gram-negative
organism in the ﬁrst bottle suggests that the increased sensi-
tivity of the NASBA assay accurately identiﬁed a BSI in this
patient much sooner than traditional culture methods. Second,
the assays allow for a faster identiﬁcation of the pathogen(s).
This was demonstrated in particular by the blood culture that
grew too poorly for timely identiﬁcation using conventional
test methods, yet the NASBA assays identiﬁed both a gram-
positive and a gram-negative organism in the blood culture at
the time the sample was ﬂagged as positive. Third, in consid-
eration of the high sensitivity of the assay, provided that patho-
gen nucleic acid extraction from the whole blood is sufﬁciently
efﬁcient, the assays could be used for detecting BSI pathogens
from a direct blood draw without the need for a primary
culture step. Studies to evaluate the potential of testing direct
blood draws and blood culture bottles at various time points
after inoculation but prior to instrument detection currently
are in progress. Additionally, studies to include other blood
culture bottle types and a more extensive testing of yeast and
fungal isolates are indicated to comprehensively assess the
performance of the assays. Finally, there is the possibility that
ampliﬁed methods lead to an increase in false-positive results
due to the detection of dead organisms or low-level contami-
nants. In such cases, as we currently must do with routine
blood cultures, the information must be evaluated in the clin-
ical context of the patient’s symptoms, disease, and underlying
comorbidities.
Wisplinghoff and colleagues reported that polymicrobial in-
fection constituted 13% of all episodes of nosocomial BSIs in
the United States (47), which is associated with higher mortal-
ity than monomicrobial BSI and tends to be more resistant to
empirical therapy. The early diagnosis of polymicrobial infec-
tion is valuable to the patient’s management, because the ad-
justment of empirical treatments often were required due to
polymicrobial episodes (5). With the capability to simulta-
neously detect multiple targets, multiplex real-time NASBA
could be not only more suitable to meet the need of rapidly
recognizing polymicrobial infections but also more efﬁcient
and cost-effective than a simplex assay. In fact, the NASBA
assays detected several gram-positive/gram-negative mixed in-
fections, including CoNS with Corynebacterium spp., CoNS
with E. coli and P. stuartii, E. faecalis with P. mirabilis, CoNS
with E. cloacae and A. baumannii, and CoNS with Alcaligenes
sp. These data suggest that the multiplex assays are highly
suitable for the primary screening of BSI pathogens.
In conclusion, this study demonstrates the feasibility of using
an NASBA-MB approach as a broad-range rapid diagnostic
method suitable for detecting BSIs.
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